You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for phentermine hydrochloride; topiramate and what is the scope of freedom to operate?

Phentermine hydrochloride; topiramate is the generic ingredient in two branded drugs marketed by Actavis Labs Fl Inc and Vivus Llc, and is included in two NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Phentermine hydrochloride; topiramate has forty patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Recent Clinical Trials for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MinnesotaEarly Phase 1
University of MinnesotaPhase 3
University of FloridaPhase 3

See all PHENTERMINE HYDROCHLORIDE; TOPIRAMATE clinical trials

Paragraph IV (Patent) Challenges for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
QSYMIA Extended-release Capsules phentermine hydrochloride; topiramate 3.75 mg/23 mg 7.5 mg/46 mg 11.25 mg/69 mg 15 mg/92 mg 022580 1 2013-07-18

US Patents and Regulatory Information for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-003 Jul 17, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-002 Jul 17, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-002 Jul 17, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-001 Jul 17, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-002 Jul 17, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Actavis Labs Fl Inc PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 204982-001 Jun 25, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-001 Jul 17, 2012 ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-002 Jul 17, 2012 ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-001 Jul 17, 2012 ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-004 Jul 17, 2012 ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-003 Jul 17, 2012 ⤷  Sign Up ⤷  Sign Up
Vivus Llc QSYMIA phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 022580-002 Jul 17, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

Country Patent Number Title Estimated Expiration
South Korea 20110042280 LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF ⤷  Sign Up
South Africa 201008840 ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY ⤷  Sign Up
Spain 2606041 ⤷  Sign Up
Mexico 2010013505 REGIMEN DE DOSIFICACION ESCALANTE PARA EFECTUAR LA PERDIDA DE PESO Y EL TRATAMIENTO DE OBESIDAD. (ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY.) ⤷  Sign Up
Chile 2010001365 Uso de fentermina en combinacion con topiramato para tratar la obesidad mediante una reduccion de peso en una persona. ⤷  Sign Up
Chile 2010001366 Composicion farmaceutica de liberacion controlada que comprende topiramato, celulosa microcristalina y metilcelulosa; preparado farmaceutico que la comprende, util para tratar la obesidad, diabetes o una afeccion relacionada. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2317997 CA 2021 00049 Denmark ⤷  Sign Up PRODUCT NAME: PHENTERMIN OG TOPIRAMAT; NAT. REG. NO/DATE: 63166, 63167, 63168, 63169 20210705; FIRST REG. NO/DATE: IS IS/1/21/018/01-04 20210212
2317997 2190050-1 Sweden ⤷  Sign Up PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212
2317997 CR 2021 00049 Denmark ⤷  Sign Up PRODUCT NAME: PHENTERMIN OG TOPIRAMAT; NAT. REG. NO/DATE: 63166, 63167, 63168, 63169 20210705; FIRST REG. NO/DATE: IS IS/1/21/018/01-04 20210212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.